Previous Page  3 / 5 Next Page
Information
Show Menu
Previous Page 3 / 5 Next Page
Page Background

Page 20

Notes:

conferenceseries

.com

Volume 10

Journal of Cancer Science & Therapy

Oncologists 2018

May 24-25, 2018

May 24-25, 2018 Osaka, Japan

22

nd

Global Annual Oncologists Meeting

Nupharidines enriched leaf extract of Nuphar lutea reduces experimental melanoma metastases

Jacob Gopas

1

,

2

, Fishman D

2

, Eilam B

2

, Golan-Goldhirsh A

2

and Ozer J

2

1

Soroka Medical Center, Israel

2

Ben-Gurion University of the Negev, Israel

N

uphar lutea

L. SM., leaf and rhizome extracts (NUP), contain nupharidines as active ingredients. Nupharidines

belong to the sesquiterpene lactones class of a naturally occurring plant terpenoids. This family of compounds has

gained considerable interest for treating infection, inflammation and cancer. NF-кB is a central, downstream regulator of

inflammation, cell proliferation and apoptosis. In our previous work we demonstrated strong inhibition of NF-кB activity and

induction of apoptosis by NUP. In addition, NUP exhibited anti-inflammatory properties and partial protection from LPS-

induced septic shock by modulating ERK pathway and cytokine secretion in macrophages. In the present study, we examined

the effect of NUP in a B16 melanoma experimental murine lung metastasis model and its ability to affect the ERK and NF-кB

pathways in variety of cell lines. We showed that NUP and cisplatin combined treatment was synergistic and reduced the lung

metastatic load. In addition, NUP treatment inhibited TNFα-induced IкBa degradation and NF-кB nuclear translocation.

We also observed that NUP induced ERK activation. Furthermore, ERK inhibition prevented NF-кB inactivation by NUP.

Interestingly, NUP treatment induced ERK activation in a human melanoma cell line, expressing BRAF mutation. Overall, our

work implies that co-administration of NF-кB inhibitors with standard anticancer drugs or radiotherapy, may act as sensitizers

or as inhibitors of multidrug resistance.

Biography

Jacob Gopas has completed his BSc from Bar-Ilan University, Israel, PhD from Albert Einstein College of Medicine, USA and Post-doctorate from Ben-Gurion

University. He is a Professor, Head of the Laboratory of the Institute of Oncology, Soroka University Medical Center, Israel and teaches cell and cancer biology.

His research includes basic and clinical cancer biology, Hodgkin’s lymphoma, and new plant compounds against inflammation, pathogens and cancer. He has

published more than 90 articles together with Israeli, German, Indian and American scientists and physicians and holds several patents (founded by the Israel

Science Foundation, Israel Ministry of Health, Israel Ministry of Science, Israel Cancer Association and NIH).

[email protected]

Jacob Gopas et al., J Cancer Sci Ther 2018, Volume 10

DOI: 10.4172/1948-5956-C3-129